JAZZ News and Press, Jazz Pharmaceuticals plc From 08/09/23

Jazz Pharmaceuticals Announces Second Quarter 2023 Financial Results and Raises 2023 Full Year Financial Guidance PR Newswire – Strong execution delivered second quarter 2023 total revenues of $957 million – – Commercial excellence drove continued adop...

Jazz Pharmaceuticals enters into Letter of Intent with the pan-Canadian Pharmaceutical Alliance (pCPA) for Rylaze®, helping address the unmet need of acute lymphoblastic leukemia and lymphoblastic lymphoma patients across Canada Canada NewsWire MISSISSAUGA, ON , ...

Jazz Pharmaceuticals to Report 2023 Second Quarter Financial Results on August 9, 2023 PR Newswire DUBLIN , July 26, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2023 second quarter financial results on We...

2023-07-25 04:47:39 ET Summary Jazz Pharmaceuticals' current valuation is significantly lower than the sector average, despite strong margins and a positive growth outlook, presenting a potential investment opportunity. The company is making progress in its clinical trials and is ...

2023-07-21 14:01:24 ET Summary Jazz Pharmaceuticals' share price has languished in FY'22 with a number of pressures on its Xywav label. The FDA has supported the competing Lumryz label, stating it is clinically superior to Xywav, chiefly due to its once-nightly dosing regimen. ...

Jazz Pharmaceuticals Receives CHMP Positive Opinion for JZP458 (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma PR Newswire DUBLIN , July 21, 2023 /PRNewswire/ -- Jazz Pharmaceutica...

2023-07-20 15:26:42 ET Summary Avadel Pharmaceuticals plc finally won approval of Lumryz™ (sodium oxybate), despite cutthroat opposition from Jazz Pharmaceuticals plc. Potential sales estimate is $3bn. Avadel Pharmaceuticals is flying high, as it well should, but I am a...

2023-06-20 06:39:41 ET Summary Today, we revisit an oncology focused developmental concern called Zymeworks, Inc. The company continues to advance its lead drug candidate, has a huge potential partnership with Jazz Pharmaceuticals and a large cash hoard. The stock has spent mo...

2023-06-08 16:50:50 ET Best Marijuana Stocks To Watch Long Term Do you intend to invest in marijuana stocks in 2023?  Over the last decade, the cannabis industry has grown incredibly, transitioning from a taboo subject to a respectable and wealthy corporate sector. As the globa...

Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers PR Newswire Results presented today at ASCO 2023 and concurrently published in The Lancet Oncology demonstrate meanin...